Antibody-drug Conjugates (ADCs) in Relapsed/Refractory Multiple Myeloma: from Bench to Bedside

Antibody-drug Conjugates (ADCs) in Relapsed/Refractory Multiple Myeloma: from Bench to Bedside is organized by Springer Healthcare IME.

Description:
Chaired by Mohamad Mohty with Salomon Manier, Suzanne Trudel and Rakesh Popat this 1 hour 15 minute hybrid symposium focused on providing delegates with the most recent knowledge on antibody-drug conjugates (ADCs) and to help enhance their confidence in the use of these novel agents in clinical practice in order to improve the management of patients with relapsed/refractory multiple myeloma (RRMM) and achieve optimal clinical outcomes.

Learning objectives:
After viewing the webcast, you will be able to:

• Distinguish and explain the different mechanisms of action of ADCs in RRMM and their clinical implications
• Analyze the latest clinical data available for ADCs in RRMM
• Apply practical considerations in the management of patients with RRMM